• Patient-Derived 3D Spheroids in Prostate Cancer

  2026-08-22

  The reference study established viable three-dimensional spheroid cultures from organ-confined prostate cancer tissue obtained during radical prostatectomy. Its findings show that these patient-derived cultures preserve key epithelial and androgen receptor-associated features, tolerate cryopreservation, and support comparative drug-response testing, creating a practical bridge between tissue pathology and translational prostate cancer research.

• From mRNA Trafficking to Translational Confidence

  2026-08-22

  Translational mRNA research increasingly depends on measuring not only whether a construct enters cells, but where it travels, whether it remains functional, and how delivery biology shapes therapeutic output. This thought-leadership article connects those measurement needs to the stroke-focused mRNA nanoparticle work reported in ACS Nano and positions ARCA Cy5 EGFP mRNA (5-moUTP) as a practical reporter for building more decision-ready delivery studies.

• Caspase-3, Coronin 1B, and Melanoma Motility

  2026-08-21

  A 2025 Cell Death and Disease study identifies a non-apoptotic role for caspase-3 in melanoma migration and invasion. The work links constitutive cytoskeletal caspase-3 to coronin 1B activity and places SP1 upstream of CASP3 expression, refining how apoptosis-associated proteins should be interpreted in cancer biology.

• Gap19 for Cx43 Hemichannel Research

  2026-08-20

  Gap19 is a selective connexin 43 hemichannel blocker for separating Cx43 hemichannel signaling from gap junction communication. Its value spans astrocyte ATP-release assays, AngII-driven macrophage polarization, and translational models of cerebral ischemia, provided concentration, formulation, and route are controlled carefully.

• 2-D08: Selective Sumoylation Inhibition

  2026-08-20

  2-D08, also called 2’,3’,4’-trihydroxyflavone, is a selective posttranslational modification inhibitor that blocks SUMO transfer from UBC9-SUMO to substrate proteins. Its strongest reported application is mechanistic sumoylation inhibition in cancer research, including topoisomerase I sumoylation inhibition in breast cancer cells, while animal and clinical validation remains unavailable.

• Caspase-3, NDUFS1, and ROS in Trichothecene Injury

  2026-08-19

  This non-peer-reviewed preprint identifies a caspase-3/NDUFS1 pathway that links trichothecene exposure to mitochondrial complex I disruption and ROS amplification, while also implicating ER-localized ERO1α as an independent oxidative source. Its combined in vivo, in vitro, inhibition, expression-suppression, and cleavage-site-mutant design offers a useful framework for separating mitochondrial dysfunction from broader oxidative stress.

• Angiotensin I/II (1-5): RAS Workflow Guide

  2026-08-19

  Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for controlled renin-angiotensin system experiments involving blood pressure and aldosterone-related readouts. It is intended for cardiovascular and renal research workflows, not unrelated peptide-signaling studies, and its water insolubility requires deliberate solvent and vehicle controls.

• Prochlorperazine Workflows for Melanoma Research

  2026-08-18

  Prochlorperazine is a dopamine D2 receptor antagonist that can connect receptor pharmacology with practical melanoma, migration, and viral-entry assays. This workflow emphasizes concentration selection, solvent control, time-of-addition experiments, and troubleshooting so researchers can distinguish pathway-specific effects from general cytotoxicity.

• Gentamycin Sulfate: From Ribosome to Resistance

  2026-08-18

  A translational framework for using Gentamycin Sulfate to connect bacterial protein synthesis, ribosome function, phenotypic susceptibility, and carbapenemase-gene transmission research in Gram-negative models.

• Tetracycline Hydrochloride in Translational Research

  2026-08-17

  A mechanism-first guide to positioning Tetracycline Hydrochloride in antimicrobial assays, skin microbiome studies, and translational workflows—while distinguishing ribosomal inhibition from emerging ROS-based therapeutic strategies.

• Biomimetic CaCO3 Nanoparticles for GBM Sono-Immunotherapy

  2026-08-17

  Zhao et al. developed cRGD-modified cancer-cell-membrane-coated calcium carbonate nanoparticles for IL-12 mRNA delivery to glioblastoma. The platform combines tumor targeting, ultrasound-triggered necroptosis, and cytokine expression to strengthen antitumor immunity, while also illustrating design principles for evaluating targeted mRNA delivery in difficult tissue environments.

• Nirmatrelvir: From 3CLpro Mechanism to Assay Design

  2026-08-16

  Nirmatrelvir (PF-07321332) is a targeted SARS-CoV-2 3CL protease inhibitor for mechanistic antiviral research. This guide moves beyond basic mechanism to show how structural biology, docking evidence, compound handling, and orthogonal assay design can improve SARS-CoV-2 replication inhibition studies.

• Gap26 in 3D Osteocyte Calcium Signaling

  2026-08-15

  Learn how Gap26 can turn a pulsatile fluid-flow osteocyte model into a controlled test of connexin 43-dependent calcium waves and ATP signaling. This workflow combines practical peptide handling, PUFFS-compatible dosing, quantitative imaging, and troubleshooting for more interpretable 3D mechanobiology experiments.

• NBC19: A NLRP3 Inflammasome Inhibitor for Translation

  2026-08-14

  A translational framework for using NBC19 to connect NLRP3 biology, IL-1β signaling, and emerging evidence on circulating giant cancer macrophages and metastatic niche formation.

• LDN-193189 in BMP Signaling: Practical Workflows

  2026-08-14

  Learn how to use LDN-193189 as a focused ALK inhibitor for dissecting BMP-driven epithelial degeneration, Smad signaling, and barrier phenotypes. This guide translates intestinal research into reproducible cell, tissue, and animal workflows while highlighting formulation limits and rescue-assay pitfalls.

8053 records 1/537 page Next 12345 下5页 Last page